Anti-Inhibitor Coagulant Complex
- Atc Codes:B02BD03
Table of contents
- Brand Names
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Feiba; Belgium: Feiba; Bulgaria: Feiba; Czech Republic: Feiba; Denmark: Feiba; Estonia: Feiba; Finland: Feiba; France: Feiba; Germany: Feiba; Hungary: Feiba; Italy: Feiba; Latvia: Feiba; Lithuania: Feiba; Malta: Feiba; Netherlands: Feiba; Poland: Feiba; Portugal: Feiba; Romania: Feiba; Slovakia: Feiba; Spain: Feiba; Sweden: Feiba; UK: Feiba.
North America
Canada: Feiba; USA: Feiba.
Latin America
Argentina: Feiba.
Asia
Japan: Feiba.
Drug combinations
Chemistry
Pharmacologic Category
Antihemorrhagic Agents; Hemostatics. (ATC-Code: B02BD03).
Mechanism of action
Therapeutic use
Hemophilia A and B patients with factor VIII inhibitors who are to undergo surgery or those who are bleeding.
Pregnancy and lactiation implications
Reproduction studies have not been conducted. Use with caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to any component of the formulation. Disseminated intravascular coagulation. Fibrinolysis. Patients with normal coagulation mechanism.
Warnings and precautions
Use with caution in patients at risk for thrombotic events and in hepatic impairment. Products may contain minute amounts of factor VIII (may cause an anamnestic response) and natural rubber latex. Product of human plasma (may potentially contain infectious agents).